Cargando…
Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis
Dipyridamole, apart from its well-known antiplatelet and phosphodiesterase inhibitory activities, is a promising old drug for the treatment of pulmonary fibrosis. However, dipyridamole shows poor pharmacokinetic properties with a half-life (T(1/2)) of 7 min in rat liver microsomes (RLM). To improve...
Autores principales: | Huang, Meng-Xing, Chen, Yan-Quan, Liu, Run-Duo, Huang, Yue, Zhang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182104/ https://www.ncbi.nlm.nih.gov/pubmed/35684390 http://dx.doi.org/10.3390/molecules27113452 |
Ejemplares similares
-
The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022) -
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α(1)-acid glycoprotein binding
por: Curtin, N J, et al.
Publicado: (1999) -
Fatty Acid Metabolism and Idiopathic Pulmonary Fibrosis
por: Geng, Jing, et al.
Publicado: (2022) -
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020) -
Dipyridamole ameliorates doxorubicin-induced cardiotoxicity
por: Alyasiry, Esraa, et al.
Publicado: (2022)